Journal Guide
Publishing in The Lancet Oncology: Fit, Timeline & Submission Guide
Practice-changing oncology with lightning-fast decisions: where global cancer research meets clinical impact
Should you submit here?
Submit if will oncologists change how they treat patients after reading your paper. Be careful if promising early results belong in specialty journals.
35.9
Impact Factor (2024)
~8%
Acceptance Rate
~14 days (very fast)
Time to First Decision
Readiness Scan
See whether your manuscript clears Lancet Oncology’s editorial screen.
Free 1 to 2 minute scan. Get a fit score, top issues, and the specific Lancet Oncology desk-reject patterns flagged before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
What Lancet Oncology Publishes
The Lancet Oncology publishes cancer research that changes practice globally. Part of the Lancet family, it combines the rigorous editorial standards of The Lancet with deep oncology expertise. They want studies that oncologists worldwide will discuss at tumor boards the week they're published.
- Phase 3 clinical trials that establish new standards of cancer care
- Global cancer epidemiology and health equity research
- Practice-changing diagnostic and therapeutic innovations
- Cancer policy research with international implications
- Real-world evidence studies that complement trial data
Editor Insight
“Lancet Oncology serves the global oncology community. We want research that will change practice in Mumbai as much as in Manhattan. If your findings only apply to well-resourced settings, consider whether the research addresses truly global cancer challenges.”
What Lancet Oncology Editors Look For
Practice-changing clinical impact
Will oncologists change how they treat patients after reading your paper? The bar isn't statistical significance; it's clinical significance that matters globally.
Global cancer perspective
Like all Lancet journals, global relevance matters here more than most journals. How does your research apply across healthcare systems, especially in resource-limited settings?
Exceptionally fast editorial process
Lancet Oncology prides itself on rapid decisions. Time-sensitive cancer research gets priority. Be prepared for quick turnaround and rapid revision cycles.
Multidisciplinary oncology relevance
Your work should matter to medical oncologists, surgical oncologists, radiation oncologists, and related specialists. Narrow subspecialty appeal limits impact.
Patient-centered outcomes
Overall survival, quality of life, patient-reported outcomes: these matter as much as response rates. Cancer care isn't just about tumor shrinkage.
Health equity considerations
Cancer disparities, access to care, and outcomes across populations are increasingly important. Address equity explicitly when relevant.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past Lancet Oncology's editorial review:
Submitting Phase 2 trials as practice-changing
Promising early results belong in specialty journals. Lancet Oncology wants definitive Phase 3 data that establishes new standards of care.
Single-country studies without global framing
If your study is from one healthcare system, articulate relevance to other contexts. What's generalizable? What's system-specific?
Ignoring health equity dimensions
Cancer disparities are a global crisis. If your research has implications for equity or access, failing to address this is a missed opportunity.
Focusing only on tumor response
Quality of life, functional status, and patient experience matter. A treatment that shrinks tumors but destroys quality of life needs careful evaluation.
Slow response to editorial requests
Lancet Oncology moves fast. If you can't commit to rapid revisions and quick responses, consider whether this is the right venue.
Missing global cancer burden context
How does your research address major cancer challenges worldwide? Connection to global cancer priorities strengthens submissions.
Does your manuscript avoid these patterns?
The Free Readiness Scan reads your full manuscript against Lancet Oncology's criteria and flags the specific issues most likely to cause rejection.
Insider Tips from Lancet Oncology Authors
Speed is genuinely valued and expected
14-day editorial decisions aren't marketing; they're real. If your research is time-sensitive (new drug approval, emerging resistance), this is your venue.
Global health framing opens doors
Even if your study is from a high-income country, discussing relevance to global cancer care aligns with Lancet priorities.
Real-world evidence complements trials
Registry studies, population-based cohorts, and effectiveness research that validate trial findings in practice are increasingly valued.
Lancet Commissions shape priorities
Current Lancet initiatives (cancer and climate change, cancer equity, etc.) influence editorial priorities. Alignment with these themes helps.
Phase 3 negative trials can be published
Well-designed trials showing treatments don't work are valuable. They prevent adoption of ineffective therapies globally.
Quality of life data strengthens submissions
Patient-reported outcomes, functional status, and quality of life measures are increasingly required for cancer trials.
International collaborations are prized
Multi-country studies, especially with meaningful LMIC participation, align with Lancet's global vision.
Editorial commentary can accompany papers
High-impact papers often receive commissioned commentary. This amplifies reach and influence within the oncology community.
The Lancet Oncology Submission Process
Presubmission inquiry (optional)
Response within 1 weekBrief pitch for time-sensitive or unusual studies. Most submissions go directly to full submission.
Full submission
Initial decision ~14 daysComplete manuscript emphasizing clinical impact and global relevance. Clear trial registration and adherence to reporting guidelines required.
Editorial assessment
~1 weekRapid evaluation of practice impact, global relevance, and methodological rigor. High desk rejection rate.
Peer review
2-3 weeksExpert oncologists and methodologists. Focus on clinical significance and implementation potential.
Decision and revision
Rapid turnaround expectedFast decisions with focused revision requests. Multiple rounds possible but typically efficient.
Lancet Oncology by the Numbers
| 2024 Impact Factor(Clarivate JCR, top oncology journal) | 51.1 |
| Submissions per year | ~2,500 |
| Acceptance rate | ~8% |
| Time to first decision | 14 days median |
| Desk rejection rate | ~75% |
| Post-review acceptance | ~30% of reviewed |
| Monthly publication | 12 issues/year |
| Global readership | Part of 1M+ Lancet family readers |
Before you submit
Lancet Oncology accepts a small fraction of submissions. Make your attempt count.
Start with the Free Readiness Scan. Unlock the Full Review from $49, with local pricing shown before checkout. If you need deeper submission planning, choose the Submission-Ready Dossier. The full report is calibrated to Lancet Oncology.
Article Types
Article
3,500 wordsFull reports of practice-changing cancer research
Fast-Track Article
Shorter; expedited processTime-sensitive findings requiring urgent publication
Review
4,000 wordsIn-depth reviews of important oncology topics
Personal View
1,200 wordsOpinion pieces on cancer policy and practice
Landmark Lancet Oncology Papers
Papers that defined fields and changed science:
- Herceptin in HER2-positive breast cancer - HERA trial (Piccart-Gebhart et al., 2005)
- Pembrolizumab in melanoma - KEYNOTE-001 (Robert et al., 2015)
- CAR-T therapy in acute lymphoblastic leukemia (Maude et al., 2018)
- PARP inhibitor maintenance in ovarian cancer - SOLO1 (Moore et al., 2018)
- Durvalumab after chemoradiotherapy in lung cancer - PACIFIC (Antonia et al., 2017)
Preparing a Lancet Oncology Submission?
Get pre-submission feedback from reviewers who've published in Lancet Oncology and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? See Expert Review Options
Primary Fields
Browse by Field
Related Journal Guides
- Publishing in Nature
- Publishing in New England Journal of Medicine
- Publishing in JAMA (Journal of the American Medical Association)
- Publishing in Nature Medicine
- Publishing in Journal of Clinical Oncology
Latest Journal-Specific Guides
- Submission guideHow to Submit to Lancet Oncology: Complete GuideA practical Lancet Oncology submission guide for authors deciding whether the paper is clinically mature, globally relevant, and package-ready.
- Journal assessmentIs Lancet Oncology a Good Journal? Impact Factor, Scope, and Fit GuideLancet Oncology JIF 35.9 publishes practice-changing cancer research with a global perspective. 75% desk rejection rate. How it compares to JCO, Annals of Oncology, and JAMA Oncology.
- Desk rejectionHow to Avoid Desk Rejection at Lancet OncologyAvoid desk rejection at Lancet Oncology with practice-changing evidence, global relevance, and defensible trial design.
- Review timelineLancet Oncology Review Time: What to Expect From Submission to DecisionLancet Oncology review time: oncology research with practice-changing implications for clinical oncologists.
More Guides for This Journal
- Acceptance rateLancet Oncology Acceptance Rate 2026: How Selective Is It?Lancet Oncology is commonly estimated to accept about 8-10% of submissions. 70-80% desk-rejected. What the numbers mean for clinical oncology authors.
- Impact factorLancet Oncology Impact Factor 2026: 35.9 - The Top Clinical Oncology JournalLancet Oncology impact factor is 35.9 (JCR 2024). Q1, rank 8/326 in Oncology. h-index 511. APC $6,300. Trend, acceptance rate, and what editors want.
- Publishing costsLancet Oncology APC and Open Access: High IF, High Price, and Limited Institutional CoverageLancet Oncology charges ~$5,450-$6,500 for open access. IF ~42. Excluded from most Elsevier R&P deals. Full cost breakdown and oncology journal comparisons.
- Submission processLancet Oncology Submission Process: What Happens After You UploadA practical Lancet Oncology submission process guide covering what happens after upload, what editors screen first, and where papers lose momentum.
- Manuscript prepThe Lancet Oncology Response to Reviewers: How to Answer the Statistical Reviewer and Win (2026)How to write a point-by-point response to reviewers for The Lancet Oncology, where a separate statistical reviewer runs in parallel with clinical referees and the revision bar is re-analysis, not rewording.
- Publishing guideIs Lancet Oncology Indexed in PubMed? Yes, and MEDLINE Is ActiveThe Lancet Oncology is indexed in PubMed and currently indexed for MEDLINE, which matters because top oncology papers need broad clinical and translational visibility.
Ready to submit to Lancet Oncology?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Lancet Oncology editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to Lancet Oncology. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to Lancet Oncology reviewers.
Need field-expert depth? See Expert Review Options